Active surveillance in favorable intermediate-risk prostate cancer: A single-center experience. Bandelier Q, Bastide C, Charvet AL, Leclercq L, et al. Prog Urol 2023 Sep 30:S1166-7087(23)00227-0. doi: 10.1016/j.purol.2023.

Read + Share

Amedeo Smart

Independent Medical Education

Bandelier Q, Bastide C, Charvet AL, Leclercq L, et al. Active surveillance in favorable intermediate-risk prostate cancer: A single-center experience. Prog Urol 2023 Sep 30:S1166-7087(23)00227-0. doi: 10.1016/j.purol.2023.
PMID: 37783635